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UROLITHIASIS AS AN EXTRAARTICULAR MANIFESTATION OF 
ANKYLOSING SPONDYLITIS 
ABSTRACT 
Ankylosing spondylitis (AS) affects sacroiliac and axial joints, as well as extraarticular organs 
such as the eye, lung, bowel and heart. Although examples of renal involvement in AS such 
as IgA nephropathy, amyloidosis and glomerulonephritis have been reported, it has not been  
emphasized that urolithiasis is frequently formed in the course of AS.  Growing evidence 
indicates that urolithiasis can be observed in AS patients and is more frequent than some other 
extraarticular involvements. In this review, we will discuss frequency and predictors of AS-
related urolithiasis and summarize the possible underlying genetic and biochemical 
mechanisms. We believe an increased awareness of urolithiasis as a complication of  AS will 
encourage future studies that will shed light on disease mechanisms and preventative 
therapies. 
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INTRODUCTION   
Ankylosing spondylitis (AS) is a chronic inflammatory disease characterized by sacroiliac 
and axial joints inflammation [1,2]. It is 2-3 times more frequent among men, and its 
prevalence is between 0.2-1.2% [3]. Extra-articular manifestations may arise in AS as a result 
of uncontrolled inflammation [4].  Anterior uveitis is one of the most common among these. 
Other examples include inflammation of the aortic root, which may lead to aortic valve 
insufficiency and conduction problems in the heart. Extraarticular manifestations also include 
apical pulmonary fibrosis, inflammatory bowel disease, nonspecific colitis, and psoriasis [4].   
The frequency of renal abnormalities has been reported to be between 10-35%, and  includes 
glomerulonephritis, IgA  nephropathy, microscopic or macroscopic hematuria, and 
amyloidosis [3].   However, none of those studies mentioned urolithiasis as a feature of AS. 
More recently, several studies have shown that urolithiasis is indeed frequently observed 
among patients with AS [5-7]. Since urolithiasis may have a relapsing nature and may 
necessitate surgical intervention [8], it may cause significant morbidity beyond the 
morbidity caused by AS alone. Furthermore, urolithiasis can cause chronic kidney disease or 
urinary system infections and obstruction. In this regard, clinicians should be aware of AS-
related urolithiasis. In this review, we will examine the literature related to urolithiasis as an 
extraarticular sign of AS, and discuss possible biochemical and genetic factors in its 
pathogenesis. We searched Pub Med, MEDLINE, EMBASE, Scopus and Web of Science 
for sources using keywords: ankylosing spondylitis, urolithiasis, nephrolithiasis, renal 
stone, kidney stone, calcium oxalate, ANKH gene, inflammatory bowel disease, Crohn’s 
disease, ulcerative colitis, bone, hypopyrophosphaturia. We also checked the references 
list of relevant studies to identify additional studies. We included studies investigating 
frequency of urolithiasis in AS; lithogenic and antilithogenic factors responsible for 
renal stone formation in AS or inflammatory bowel diseases; ANKH gene…… 
THE EVIDENCE FOR UROLITHIASIS IN ANKYLOSING SPONDYLITIS  
In 1972, Elian et al.  reported that 13.6% of  AS patients (Table 1) had urolithiasis [9].  They 
proposed that limited spinal mobility and altered pyelo-pelvic position might be an underlying 
predisposing factor for urolithiasis. In 1973, Mladevoniç reported that 8.5% of AS patients 
had kidney stones [10] compared to a reported, frequency of kidney stones of 1.9% among the 
general population of Croatia. It was also proposed that spinal ankylosis and hip joint 
involvement were risk factors for stone formation. In 1989, Jimenes Balderas et al. detected 
urolithiasis in 25% of  AS patients. Researchers also reported hyperuricemia in 5 of these 23 
patients [11].   
Based on our observation during our routine clinical practice that some of our patients with 
AS had recurrent urolithiasis, we conducted an ultrasonography (USG) based study in 2005 
[5]. We showed presence of urolithiasis in 20 (24%) of 83 AS patients.  
In 2006, Incel et al. from Turkey found 11.3% of  AS patients had urolithiasis, however, this 
rate was not different in comparison to healthy controls. They found that both lumbar and 
femoral neck bone mineral densities (BMD) were lower among AS patients with urolithiasis 
and proposed a possible relationship between osteoporosis, urolithiasis and femoral neck 
fracture [12].   
In 2006, Canales et al. evaluated the frequency of kidney stone among patients with 
spondyloarthropathy (SpA) including patients with AS, and compared the results to that of 
patients with rheumatoid arthritis (RA). The frequency of self-reported kidney stone was 
29.11% among patients with SPA and 12.5% among patients with RA [13].   
In their 2011 study with 102 AS patients, Cansu et al. investigated possible predictors of 
radiographic and functional disability, and they detected urolithiasis in 27.5% of patients with 
AS [14].   
In 2012, Lui et al. found 7.5% of 504 AS patients had urolithiasis, and they reported that 
patients with renal stones had worse functional indices compared to patients without stone. 
Additionally, the frequency of peripheral arthritis and requirement for biological drugs were 
found to be greater among patients with urolithiasis. They also stated that diseases like 
diabetes and Crohn's disease may have contributed to stone formation in these patients. The 
researchers could not find an association between presence of syndesmophytes and 
urolithiasis [15].  
In 2012, Fallahi et al. found the frequency of urolithiasis among 163 Iranian patients with AS 
was 11.7%, in comparison to 5.7 % in 7649 normal controls. They found higher values of  
Bath ankylosing spondylitis metrology index (BASMI), Bath ankylosing spondylitis 
functional index (BASFI) and Bath ankylosing spondylitis disease activity index (BASDAI) 
parameters in patients with kidney stone [16]. 
In their 2014 prospective, population based nation-wide study from Sweeden, Jakobsen et al. 
investigated frequency of kidney stone and its predictors in 8572 AS patients that were cohort 
against 39639 healthy individuals. The two groups were evaluated for comorbid diseases. At 
the beginning of the study, frequency of urolithiasis was 1.6% among AS patients and 0.7% in 
the control group. At the end of the study, these rates were 4% and 1.8%, respectively. They 
found the unadjusted Hazard Ratios of urolithiasis for AS compared to population 
comparators as 2.4 (95% CI 2.1 to 2.9). In that same study, male sex, inflammatory bowel 
disease, history of previous urolithiasis, disease severity and utilization of anti-tumor necrosis 
factor (TNF) medication were found as predictors for urolithiasis. Even after necessary 
adjustments for age, inflammatory bowel disease, history of previous urolithiasis, AS was 
found to be a risk factor for urolithiasis (2.1 (95%CI 1.8-2.4) [8]. 
In a 2015 study from Turkey, Resorlu et al. compared 38 AS patients and 38 healthy controls 
in terms of frequency of kidney stone. They found urolithiasis was present among 18.4% of 
AS patients and 10.4% of controls [17]. 
Most of these studies were conducted in centers that provided tertiary health care services and 
therefore are hampered by both selection and referral bias. Many of the studies included very 
small patient numbers. However, the Swedish cohort study included a large database making 
it less prone to bias and providing more robust statistical evidence. Based on these data, 
urolithiasis appears to be 2.5 times more frequent among AS patients in comparison to the 
general population. 
Clinical Predictors for Urolithiasis in AS Patients 
Previous studies have suggested that hip joint involvement and spinal ankyloses in AS are risk 
factors for stone formation [9, 10]. In our study, urolithiasis was associated with advanced 
age, longer disease duration [5].  Additionally, there are studies that found association 
between urolithiasis and functional and radiological severity, and male sex. The Swedish 
study suggests that previous history of urolithiasis, presence of inflammatory bowel 
disease and treatment with anti-TNF alpha are predictors for urolithiasis. Taken 
together, these studies do not provide a homogenous list of predictors for urolithiasis related 
with AS, and this may be due to differences in their designs, limitations in patient numbers 
and variations in ethnicities of study populations. 
Possible mechanism(s) for the development of urolithiasis 
The balance between lithogenic and antilithogenic factors is important for renal stone 
formation. Urolithiasis may be secondary to multiple underlying factors with a range 
underlying disease and complex mechanisms involving kidney, intestine and bone 
predisposing to disease [18]. Bone remodelling and intestinal changes in the course of AS 
may change this balance to lithogenic side (Figure 1). Important antilithogenic factors include 
urinary citrate and magnesium. Hypercalciuria, hyperoxaluria, hyperuricemia, reduced urinary 
flow and dehydration are all lithogenic factors [18,19]. In AS, these conditions may be the 
consequence of a wide variety of diseases causing disturbances in intestinal absorption, renal 
resorption and bone remodelling. 
The possible role of gastrointestinal system 
Recognition of the type of the stone may shed light on its pathogenesis; however, our 
knowledge about the stone types in AS is limited. The most common type of kidney stones 
observed in the general population is calcium oxalate (CaOx). For formation of CaOx stones, 
hypercalciuria and hyperoxaluria are the most common biochemical risk factors [18].  
Urolithiasis is also known to be frequent (10.5%) among patients with Crohn's disease [20], 
an inflammatory bowel diseases. The majority of the stones found in Crohn's disease are also 
CaOx stones [20]. The pathogenesis of urolithiasis occurring in Crohn's disease involves 
saponification of calcium with lipids inside the gut lumen and thereby, reduced calcium 
available for binding with oxalate, which is necessary to reduce absorption of oxalate from 
the bowel. Thus, intestinal oxalate absorption is increased, and this leads to hyperoxaluria and 
is a risk factor for stone formation in kidneys. It has not been proven that the same mechanism 
is also responsible for urolithiasis in AS, but it is likely that it may be one of the factors 
playing role in development of AS-related urolithiasis. A reciprocal clinical and genetic 
overlap exist between inflammatory bowel disease and AS. For instance, subclinical colitis is 
present in 2/3 of AS patients [21]. Intestinal biopsy examinations show that 26% of AS 
patients demonstrate a histological appearance similar to what is seen in Crohn's disease, and 
10% of the patients are diagnosed with inflammatory bowel disease [22, 23]. Genetic factors 
common to AS and inflammatory bowel diseases may have a role in this process. For 
example, HLA-B27 positivity has been reported with the rates of 85% and 33% in AS and 
inflammatory bowel diseases, respectively [23]. IL23R gene has been shown to be associated 
with AS and inflammatory bowel diseases [24,25]. van Sommeren et al. showed that AS 
patients have the largest number of risk loci that are shared with inflammatory bowel disease 
[26]. Recently calprotectin, which is an indicator of intestinal inflammation, has been shown 
to be elevated in serum and faeces of patients with AS, and it has been associated with 
radiological severity and other inflammatory parameters [27,28]. Calprotectin is especially 
important for showing macrophage-neutrophil infiltration in inflammatory bowel diseases 
[29]. Elevated levels of calprotectin in AS suggests possible role of intestinal inflammation in 
pathogenesis of AS. Also, antibodies against commensal bacteria have been detected in 
patients with AS [30], as well as in inflammatory bowel diseases. The most important of these 
antibodies is antiflagellin, whose titer has been found to be correlated with increased acute 
phase response in AS [30]. Flagellin is a molecular component on bacterial surface, and 
interacts with TLR5 and induces production of proinflammatory cytokines. Another 
interesting finding was that Gönüllü et al. found higher blood IgA levels in AS patients with 
urolithiasis compared to the AS patients who did not have urolithiasis [31]. However, we do 
not know whether there is a causal relationship between IgA and urolithiasis in AS patients. 
Shodjai-Moradi et al. found that the levels of IgA were significantly elevated in patients with 
active AS compared with patients with inactive AS or RA, or with healthy controls [32]. 
Other studies have also reported similar results in patients with AS and compared with 
patients with RA[33,34]. It has been reported that there is an association between increased 
AS disease activity and increased serum IgA levels [35]. Ardicoğlu et al suggested that the 
increase in IgA levels is a sign of an enterobacterial antigenic stimulation that occurs in the 
gastrointestinal tract during the active phase of the disease [36]. It is tempting to speculate 
that enterobacterial antigenic stimulation and subclinical colitis might lead to increase in the 
levels of IgA and hyperoxaluria. We believe that the possible relationship between IgA, 
urolithiasis and enterobacterial stimulation seems to be open to further investigations.  
 We hypothesize that one of the mechanisms responsible for development of urolithiasis in 
AS may be intestinal inflammation occurring during the course of AS, resulting in enteric 
hyperoxaluria. However, it will be necessary to know whether patients with and without 
kidney stones differ in terms of presence of intestinal inflammation and hyperoxaluria. 
 
The role of Bone 
Bone structure is compromised by AS, as the disease causes both new bone formation 
(ankylosis, syndesmophytes), and leads to osteoporosis and fractures of  the trabecular 
structure of the vertebral column [37]. Factors playing a role in the development of 
osteoporosis in AS include systemic inflammation, vitamin D deficiency, inappropriate load 
on bones due to abnormal gait and posture, malabsorption, inflammatory bowel disease and 
low body mass index [38]. İncel et al. found an association between femoral neck 
osteoporosis and urolithiasis. The authors proposed that development of urolithiasis and 
osteoporosis might be separate outcomes that stem from a common mechanism [12]. In line 
with this suggestion, some studies have illuminated the osteoporotic fractures develop more 
frequently in patients with urolithiasis than in the general popuation [39]. 
 Levels of the bone turnover markers RANK-RANK-L, DKK-1, sclerostin and 
osteoprotegerin are altered during this process [40,41]. RANK-RANK-L is activated by 
inflammatory cytokines, and it leads to resorption. Osteoprotegerin, on the other hand, has an 
antiresorptive role. In AS patients, low levels of osteoprotegerin have been detected together 
with high sRANKL/OPG ratios [42]. It is obviously important to know how the calcium 
levels change during this bone turnover within the bone structure which holds 99% of the 
body calcium. It has been reported that inflammatory cytokines such as IL-6, IL-1, TNF-alpha 
not only play a role in the inflammatory process of AS, but are involved in the osteoporosis of 
AS   [43,44]. It is well known that TNF-alpha and IL-1 are among the most powerful 
stimulators of bone resorption and are well-recognised inhibitors of bone formation [45]. 
They may also result in hypercalciuria [46]. Taken together, hypercalciuria may be expected 
in AS patients due to both immobilization and inflammatory cytokines. There are conflicting 
studies as to whether or not hypercalciuria is prevalent in patients with AS [45]. In our 2006 
study, although urinary calcium levels were increased in AS patients with urolithiasis, the 
difference was not statistically significant; nonetheless, frequency of hypercalciuria was 
higher among AS patients with urolithiasis compared to AS patients without urolithiasis [5]. 
In another study, serum calcium level was found higher among AS patients with urolithiasis 
[31]. As a conclusion, due to the limited number of urine analysis studies related with 
lithogenic and antilithogenic factors playing role in stone formation, and also because these 
studies were cross-sectional rather than involving serial analyses, it is unfortunately difficult 
to reach a definitive conclusion. Nonetheless, it can be said that both blood calcium levels and 
urinary calcium excretion are increased in some patients, which may contribute to the stone 
formation.   
 
Genes and urolithiasis in AS 
Environmental and genetic factors play important roles for development of urolithiasis. Those 
with a family history of urolithiasis have a higher risk [47]. Several recent studies have 
reported a positive family history and heritability in patients with urolithiasis [48-50]. This 
finding indicates to the importance of genetic factors. However, there are no studies which 
have proven a genetic risk factor in patients with AS-related urolithiasis. However, ANKH has 
been proposed as a genetic marker in AS pathogenesis [51-53], as well as a possible 
contributor to the stone formation [54]. ANKH encodes ANK is a transmembrane transporter 
protein which serves to transport intracellular pyrophosphate out of the cell, and thus maintain 
a balance in inorganic pyrophosphate (PYP) levels [55]. Mutations in ANKH result in 
chondrocalcinosis and craniometaphyseal dysplasias. In addition, functional loss that 
develops as a result of the mutations in ANKH leads to the arthritic process, new bone 
formations and ankylosis that are characteristics of AS [55]. Normally, inorganic 
pyrophosphate inhibits calcification [56] and pyrophosphate presents in urine and prevents 
formation of apatite crystals [57]. Hypopyrophosphaturia is therefore a risk factor for 
urolithiasis [58]. Considering a possible role of ANKH in development of urolithiasis, we 
analyzed 6 single nucleotide polymorphisms within ANKH in 23 patients with AS [54]  but 
did not find any association between ANKH polymorphism and renal stones.   
ANKH  has also significance in terms of AS. Tsui et al. reported 5-Flanking region of ANKH  
to be a novel genetic marker for AS [51]. The same researchers showed that while two 
intronic markers at the 3' end of ANKH gene were associated with AS in males, two intronic 
markers at 5'end of this gene were associated with AS in females [52]. Liu et al also showed 
that variation in ANKH influences  susceptibility to AS in Chinese patients [53]. However, no 
significant relationship between gender and ANKH  gene was identified in this study.  On the 
other hand, Pimentel Santos et al., and Timms et al. stated that ANKH was not associated with 
AS, and had no effect on the severity of the disease [59, 60]. Differences in these study results 
may have arisen from different ethnicities of the study populations, variations in case 
definitions, and differences in analytical methods for detection of ANKH marker variants. In 
summary, ANKH gene polymorphism deserves further research, which may yield interesting 
results with regards to its possible roles in AS pathogenesis and stone formation. 
TREATMENT DRUGS AND UROLITHIASIS 
Drug-induced urolithiasis has a prevalence of  0.44 % (0.59 % in women and 0.37 % in men) 
[61]. Sulfasalazine is one of drugs that induce stone formation. Acetylsulfapyridine is a 
metabolite of sulfasalazine (SSZ), which is usually used for peripheral arthritis seen in the 
course of SpA including AS. SSZ is also used in patients with RA, inflammatory bowel 
diseases and juvenile chronic arthritis. In the literature, the development of urolithiasis due to 
SSZ use has been reported in patients with psoriatic arthritis [62], juvenile chronic arthritis 
[63] and ulcerative colitis [64]. Although the renal stone formation stemming from 
acetylsulfapyridine was confirmed by reflectance infrared spectroscopy and gas 
chromatography-mass spectrometry in some case reports [65], it is not clear whether 
urolithiasis results from SSZ or disease itself. It has been reported that there was no concrete 
association between SSZ use and renal stone formation in AS patients [5]. Further studies are 
needed to elucidate the potential role of SSZ on urolithiasis. Other medications that are used 
in the treatment of AS are nonsteroidal anti-inflammatory drugs (NSAIDs) and anti-TNF-
alpha agents. In the literature, there are no conclusive data implicating anti-TNF-alpha agents 
and NSAIDs as contributors to renal stone formation in AS. However, it has been reported 
that NSAIDs may lead to papillary necrosis and sometimes mimics staghorn calculi [66]. 
Clinical importance of urolithiasis 
As a chronic disease, AS impairs life quality, increases morbidity and mortality, and increases 
health costs [67]. Patients with AS-associated urolithiasis have higher recurrence rates in 
comparison to cases of urolithiasis among the general population [8]. In one of our studies, 
among 23 patients with urolithiasis, 10 patients experienced only single attack of urolithiasis, 
whereas 13 patients had history of multiple attacks [54]. Another interesting feature of AS-
associated urolithiasis is that requirement for surgical intervention is 3 times more frequent in 
comparison to urolithiasis seen in the general population [54]. This is somewhat related to the 
more complicated course seen in AS-associated urolithiasis. In the study by Jakopsen et al., 
extracorporeal shock wave lithotripsy (ESWL was performed in 64% of patients, 
ureteroscopic procedures was performed in 25%, surgical intervention was performed in 2%, 
percutaneous nephrolithotomy was performed in 6%, and retrograde intrarenal surgery was 
performed in 3% of their patients. Predictors of surgical requirement include previous 
urolithiasis, advanced age and atherosclerotic heart disease. Requirement of surgical 
intervention in the presence of atherosclerotic disease further increases the complexity of 
these cases. 
Another downside of AS-related urolithiasis is that it can cause pyelonephritis. Unfortunately, 
there is no data from AS patients on this subject. However, 4-23% of patients with Crohn's-
associated urolithiasis develop pyelonephritis [68,69]. This rate is 10-100 times higher 
compared to the general population [70]. Some patients with AS receive anti-TNF treatment, 
and this makes them more susceptible to such complications. Recurrent renal stone 
formations and repeated pyelonephritis attacks may lead to chronic kidney disease (CKD) 
[71]. Vupputuri et al. reported that the likelihood of CKD was 2-fold higher among persons 
with history of urolithiasis [72]. Another potential risk factor for CKD in case of urolithiasis 
is percutaneous nephrolithotomy. Following this procedure, 16.4% of patients may develop 
disturbance of renal functions [73].  Therefore, both the adverse effects of the stones on 
kidneys, and interventions aimed to treat them pose threat to the renal functions.  
FUTURE IMPLICATIONS AND CONCLUSIONS 
Urolithiasis is an extra-articular manifestations of AS. There is limited data concerning the 
frequency of urolithiasis, which may be because of the little awareness on this subject. 
Increasing awareness would trigger future studies on this topic, which would help us better 
understand the ethnic and environmental factors that play role in development of urolithiasis. 
According to the limited data at hand, urolithiasis has the potential of increasing morbidity 
and mortality of the disease. For this reason, studies related with the mechanisms involved in 
development of stones are necessary. Stone formation may be attributed to multiple 
mechanisms. Combined effects of bone resorption caused by inflammatory cytokines and 
immobilization and possible hypercalciuria, increased oxalate absorption and hyperoxaluria 
resulting from intestinal inflammation, and genetic factors related with stone formation may 
create tendency towards urolithiasis. Research aimed at these mechanisms would enlighten 
this topic and offer necessary measures for prevention. Further studies including repeated 
24h urinary sampling analysing lithogenic and antilithogenic factors in urine in AS 
patients with and without a history of urolithiasis, as well as analysis of stone 
composition in AS patients, are expected to give further indications to the pathogenesis 
involved in Stone formation in AS patients. 
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